| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3979860 | Cancer Treatment Reviews | 2014 | 9 Pages |
Abstract
The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jasmijn G.M. van Kampen, Monica A.J. Marijnissen-van Zanten, Femke Simmer, Winette T.A. van der Graaf, Marjolijn J.L. Ligtenberg, Iris D. Nagtegaal,